{
    "pmcid": "10865538",
    "qa_pairs": {
        "What is the primary target of the nanobodies developed in the study?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 virus.",
            "The spike protein of the SARS-CoV-2 virus.",
            "The nucleocapsid protein of the SARS-CoV-2 virus.",
            "The membrane protein of the SARS-CoV-2 virus."
        ],
        "What is the significance of using a human framework for the synthetic library in the study?": [
            "To minimize immunogenicity when used as therapeutics in humans.",
            "To increase the binding affinity of the nanobodies.",
            "To enhance the stability of the nanobodies.",
            "To improve the solubility of the nanobodies."
        ],
        "What potential application does sdAb39 have according to the study?": [
            "COVID-19 diagnostics, therapeutics, and vaccine development.",
            "Treatment of autoimmune diseases.",
            "Development of cancer immunotherapies.",
            "Prevention of bacterial infections."
        ],
        "What was the outcome of the second stage of the phage display screening?": [
            "Identification of several promising high-affinity sdAbs.",
            "Elimination of low-affinity binders from the library.",
            "Identification of a single high-affinity sdAb.",
            "Determination of the optimal CDR3 length for binding."
        ],
        "Which specific feature of the CDR3 region was varied to maximize diversity in the synthetic library?": [
            "The length of the CDR3 region, with lengths of 10, 14, and 18 amino acids.",
            "The amino acid composition of the CDR3 region.",
            "The charge of the CDR3 region.",
            "The hydrophobicity of the CDR3 region."
        ]
    }
}